Overview

  • Product name
    Anti-Androgen Receptor antibody
    See all Androgen Receptor primary antibodies
  • Description
    Rabbit polyclonal to Androgen Receptor
  • Host species
    Rabbit
  • Specificity
    This antibody detects Androgen Receptor. This antibody does not detect estrogen, progesterone, or glucocorticoid receptors. By Western blot, this antibody detects an ~110 kDa protein representing AR from HepG2 nuclear extracts. Faint bands at 70 and 75 kDa are also detected in both immune and pre-immune sera. Immunohistochemical staining of AR in rat brain results in intense nuclear staining.
  • Tested applications
    Suitable for: WB, IHC-P, ICC, ICC/IFmore details
  • Species reactivity
    Reacts with: Rat, Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic peptide corresponding to Human Androgen Receptor aa 1-21 (N terminal).
    Sequence:

    MEVQLGLGRVYPRPPSKTYRG


    (Peptide available as ab4903)

Properties

Applications

Our Abpromise guarantee covers the use of ab3510 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 2 µg/ml. Detects a band of approximately 110 kDa (predicted molecular weight: 99 kDa).Can be blocked with Androgen Receptor peptide (ab4903).
IHC-P Use at an assay dependent concentration. PubMed: 18695799
ICC Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration. PubMed: 19996220

Target

  • Function
    Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
    Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
  • Tissue specificity
    Isoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
  • Involvement in disease
    Androgen insensitivity syndrome
    Spinal and bulbar muscular atrophy X-linked 1
    Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
    Androgen insensitivity, partial
  • Sequence similarities
    Belongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • Domain
    Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
  • Post-translational
    modifications
    Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
    Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
  • Cellular localization
    Nucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
  • Information by UniProt
  • Database links
  • Form
    There are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
  • Alternative names
    • AIS antibody
    • ANDR_HUMAN antibody
    • Androgen nuclear receptor variant 2 antibody
    • Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody
    • Androgen receptor antibody
    • androgen receptor splice variant 4b antibody
    • AR antibody
    • AR8 antibody
    • DHTR antibody
    • Dihydro testosterone receptor antibody
    • Dihydrotestosterone receptor (DHTR) antibody
    • Dihydrotestosterone receptor antibody
    • HUMARA antibody
    • HYSP1 antibody
    • KD antibody
    • Kennedy disease (KD) antibody
    • NR3C4 antibody
    • Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody
    • Nuclear receptor subfamily 3 group C member 4 antibody
    • SBMA antibody
    • SMAX1 antibody
    • Spinal and bulbar muscular atrophy (SBMA) antibody
    • Spinal and bulbar muscular atrophy antibody
    • Testicular Feminization (TFM) antibody
    • TFM antibody
    see all

Images

  • Anti-Androgen Receptor antibody (ab3510) + Nuclear extract prepared from HepG2 cells

    Predicted band size: 99 kDa

  • Immunofluorescence analysis of LNCaP cells staining Androgen Receptor with ab3510.
    Left panel = untreated cells
    Right panel = 10 nM R1881

References

This product has been referenced in:
  • Zhao S  et al. Maternal exposure to di-n-butyl phthalate (DBP) promotes epithelial-mesenchymal transition via regulation of autophagy in uroepithelial cell. Toxicology 406-407:114-122 (2018). Read more (PubMed: 30053495) »
  • Wang X  et al. Compounds from Cynomorium songaricum with Estrogenic and Androgenic Activities Suppress the Oestrogen/Androgen-Induced BPH Process. Evid Based Complement Alternat Med 2017:6438013 (2017). Read more (PubMed: 28588640) »
See all 15 Publications for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A

Answer

Thank you for taking time to compile that data and sharing it with me.It is quite clear that this antibodyhas not been performing satisfactorily in your experiments. The details provided will enable us to investigate this case further and will provide us with vital information for monitoring product quality. I thank you for bringing this problem to our attention.

I appreciate the time you have spent in the laboratory and understand your concerns. It is regrettable the results have not been successful. I am not sure why we were not forwarded this information by xxx but that is why I decided to contact you directly. We take customer complaints very seriously and aim to provide a response within 24 hours of receiving any correspondence. If you have a similar situation in the future where you have not heard from us (through xxx), please do contact us directly. As you are in Finland, you can also purchase directly from us if you prefer.

Having reviewed the data and the protocol details, I believe this product should have given satisfactory results, but it clearly has not.This is a littleperplexing as the original lot which you found to work (515591) was from the same bleed as the subsequent lots. It appears that something may have happened in the handling of the different batches. We will be looking into this further. I have requested that the antibody be retested. If you could share with me the dataobtained with lot515591 that would be veryhelpful in aiding our internal investigation further.

I apologize for the inconvenience this problem has caused you. Although the Abpromise technically only covers a product for 6 months following purchase, in this case I am willing to extend the cover and offeryou a replacement or a refund of all the lots you have found not to be functional. In order to do this I will need to know the order numbers of each purchase. I have looked back at our records and have found two orders that I think are yours:

Order number 659726 (18/03/2010) and 659080 (17/03/2010) both delivered to xxxxx(xxxxx Finland) through xxxxx.

I cannot find reference to any other orders. Did you use a different delivery address prior to 2010? I can probablyfind the additionalorders ifyou can giveme a delivery address and an approximatedate of the order.

We have several alternative antibodies to Androgen Receptor but the one that I would suggest trying as an alternative is https://www.abcam.com/Androgen-Receptor-antibody-EP670Y-ab52615.html. This is a rabbit monoclonalwhichhave been found to havevery goodbindingproperties. This antibody hasbeen successfully used in westernblotting of the protein (clean band at the expectedsize)and is compatible withmouse, human and rat samples. If you would like, I can arrange for you tofirst try alot of this antibody, thenif you don'tlike the results, you can decide to have the full refund ofall your faulty products.

Thank you for your cooperation. I look forward to hearing from you with details of how you would like to proceed.

Read More

Answer

I was informed by the source of ab3510 that the reason why there is no recommended dilution for ab3510 is that the current lot has not been tested in IHC and therefore we do not know what dilution it should be used at. In light of this we are currently considering removing IHC as a tested application and removing the image too. I would recommend to try a range of dilutions in a preliminary experiment (1:10, 1;50, 1:100, 1:200, 1:500) and optimizing following the results. I'm sorry I couldn't help you more. If you experience problems please do not hesitate to contact me and I can look into details of your protocol to help more and should the problem be antibody related offer you a refund,

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up